J&J Ends Rheumatoid Arthritis Program After Disappointing Mid-Stage Data
Nipocalimab, approved as Imaavy for generalized myasthenia gravis earlier this year, failed to show significantly added benefit when used with an anti-TNFα therapy in patients with rheumatoid arthritis.Read more:
biospace.comBiotechnology